Amarin completes individual randomization in AMR101 Phase 3 trial in sufferers with high triglyceride levels Amarin Company plc , a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, reported the completion of patient randomization for its ANCHOR trial today, a pivotal Phase 3 trial of AMR101 treat pe with tadalafil . THE BUSINESS indicated that it anticipates reporting top-line results out of this trial in Q2 2011 . The ANCHOR trial is a multi-center, placebo-managed, randomized, double-blind, 12-week pivotal study to judge the efficacy and security of 2 grams and 4 grams of AMR101 in individuals with high triglyceride amounts from 200 mg/dL to significantly less than 500 mg/dL who are also on statin therapy.
The finding brings brand-new hope for IBM individuals with weakness, inflammation or atrophy of muscles within their fingers, wrists, quadriceps or forearms. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health. ‘The immunization wasn’t a complete fix, but it considerably slowed the deterioration of motor function inside our IBM mice,’ said Frank LaFerla, director of UC Irvine’s Institute for Brain Aging and Dementia. ‘I hope our discovery qualified prospects to medical trials and, eventually, a vaccine for folks suffering from or at risk for IBM.’ Related StoriesResearchers reveal why malaria vaccine provides just moderate security among vaccinated childrenResearch provides prospects for new strategies to develop HIV vaccineNew initiative released to accelerate search for effective HIV vaccineStudy results appear Wednesday, May 13, in The Journal of Neuroscience.